Stoke Therapeutics, Inc. revenue breakdown overview

Stoke Therapeutics, Inc. revenue for the last year amounted to 36.55 M USD, the most of which — 36.55 M USD — came from its highest performing source at the moment, Antisense Oligonucleotides, the year earlier bringing 8.78 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Stoke Therapeutics, Inc. 36.55 M USD, and the year before that — 8.78 M USD.